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Objective: The objective of this eight week, single-center, two-cell, double-blind, and ran-
domized clinical study was to evaluate the dentin hypersensitivity reduction efficacy of a
mouthwash using Pro-ArginTM Mouthwash Technology containing 0.8% arginine, PVM/MA
copolymer, pyrophosphates, and 0.05% sodium fluoride in an alcohol-free base (‘‘Arginine
Mouthwash’’) compared to an ordinary mouthwash without any active ingredients (‘‘Nega-
tive Control’’).
Methods: Qualifying subjects who presented two hypersensitive teeth with a tactile hyper-
sensitivity score between 10 and 50 g of force, and an air blast hypersensitivity score of 2 or 3
participated in this study and were randomized into one of two treatment groups. Subjects
brushed with the toothbrush and fluoride toothpaste provided and then rinsed with 20 mL of
their assigned mouthwash for 30 s twice daily. Subjects refrained from eating or drinking for
30 min after rinsing. Dentin hypersensitivity assessments, as well as examinations of oral
hard and soft tissues, were conducted at the baseline visit and again after two weeks, four
weeks and eight weeks of product use.
Results: Ninety (90) subjects entered and completed the eight week study. After two weeks,
four weeks and eight weeks of product use, subjects in the Arginine Mouthwash group
exhibited statistically significant ( p < 0.05) improvements in mean tactile and air blast
hypersensitivity scores as compared to the Negative Control Mouthwash.
Conclusion: The results of this study support the conclusion that the Arginine Mouthwash
provides a significant reduction in dentin hypersensitivity after eight weeks of product use
as compared to a Negative Control mouthwash.
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Dentin hypersensitivity has been the subject of many
scientific publications over the past several years. The* Corresponding author. Tel.: +86 285582167.
E-mail address: hudeyu@vip.sina.com (D. Hu).
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Open access under CC BY-NC-ND license. articles have ranged from discussions of its causes and
management to current and new agents that have
been incorporated into oral health product formulations
which have been clinically proven to treat dentin hyper-
sensitivity.1–8
j o u r n a l o f d e n t i s t r y 4 1 s ( 2 0 1 3 ) s 2 6 – s 3 3 S27The term dentin hypersensitivity is almost always de-
scribed as a short episode of sharp pain that arises from
exposed dentin, typically in response to chemical, thermal,
tactile and osmotic stimulation.9 Up to 57% of patients have
been reported to be affected by this condition.10–13 Most
hypersensitive teeth are accompanied by gingival recession,
the result of periodontal disease, periodontal therapy or
improper brushing.14,15 In a healthy tooth, the dental pulp is
covered by dentin which is protected by enamel above the
gingiva and cementum and the gingiva themselves below the
gingiva.16 Just as the enamel covers and protects the
underlying dentin from external stimuli, the gingiva protects
the underlying cementum and root dentin. When the gingiva
recedes, the protective cementum can be easily removed so
that the dentin tubules are exposed and open, thereby
transmitting the pain producing stimuli.
The hydrodynamic theory of dentin hypersensitivity
proposed by Brannstrom in 1963 remains the widely accepted
theory of how dentin hypersensitivity occurs.17,18 It attributes
fluid movement within exposed dentin tubules to the
transmission of painful sensation. Specifically, non-noxious
stimuli at the tooth surface can trigger fluid movement within
the dentin tubules affecting the pulpal mechanoreceptors and
resulting in the sensation of pain. Under a microscope, a
sensitive tooth shows widened dentin tubules, as much as two
times larger than tubules of normal dentin, and in greater
number per area compared to a tooth without dentin
hypersensitivity.19 Treatment and prevention of dentin
hypersensitivity focuses on eliminating the ability of external
stimuli to trigger pain. Currently one of two approaches is
typically used. The first is to block the triggers of nerve activity
by treating the tooth with a physical or chemical agent that
forms a layer which mechanically occludes the dentin tubules
and prevents pulpal fluid flow. The second is by interrupting
the neural response to pain stimuli by delivering potassium
salts to the tubule area where they have a depolarizing effect
on electrical nerve conduction, causing nerve fibers to be less
excitable to the stimuli, thereby reducing a patient’s sensation
of pain. The occluding agent or potassium salt is generally
delivered by incorporating it into an oral health product so that
patients can treat the condition at home during normal oral
hygiene procedures.20–23
The most common products used by patients seeking pain
relief from dentin hypersensitivity are desensitizing denti-
frices. In the past, these dentifrices usually contained
potassium salts – potassium nitrate, potassium citrate,
potassium chloride – which are believed to have a depolarizing
effect on electrical nerve conduction, causing nerve fibers to
be less excitable to the stimuli.24–39 Recently, a new dentifrice
product was introduced which has been clinically proven to
provide superior dentin hypersensitivity relief. The dentifrice
contains 8% arginine, calcium carbonate and 1450 ppm
fluoride as sodium monofluorophosphate. Arginine, an amino
acid, historically has been studied for its potential oral health
benefits. It was shown that a combination of arginine and
calcium carbonate when deposited on exposed dentin
surfaces is able to physically block and seal open dentin
tubules. The novel dentifrice has been reported in numerous
clinical studies to provide superior relief of dentin hypersen-
sitivity when compared to a leading sensitivity dentifricecontaining potassium ion.40–42 This technology has also been
shown to provide instant relief after a single direct topical
application of the dentifrice.43–45
There are a variety of dental products known to success-
fully address dentine hypersensitivity. A new mouthwash
using the Pro-ArginTM Mouthwash Technology was designed
to effectively reduce dentin hypersensitivity. The mouthwash
efficacy is based on occlusion of the dentin tubules,46,47
provided by a proprietary formulation of arginine, PVM/MA
copolymer and pyrophosphates.
Therefore, the aim of this eight week, single-center, two-cell,
double-blind, and randomized clinical study conducted in the
Chengdu, China area, was to evaluate the dentin hypersensi-
tivity reduction efficacy of two mouthwashes, one containing
0.8% arginine, PVM/MA copolymer, pyrophosphates, and 0.05%
sodium fluoride (‘‘Arginine Mouthwash’’) and the other con-
taining 0.05% sodium fluoride (‘‘Negative Control’’).
2. Materials and methods
This clinical study employed a randomized assignment,
double-blind, two-treatment, parallel-group design. Adult
subjects from the Chengdu, China area were enrolled in the
study.
2.1. Sample size determination
The sample size of 90 (45 per group) was determined based on
a standard deviation (SD), for the response measure tactile
sensitivity (or air blast) of 3.34 (or 0.31), a significance level of
a = 0.05, a 10% attrition rate and an 80% level of power. The
study was powered to detect a minimal statistically significant
difference between the study means of 20%. The sample size
calculation utilized a historical data from previous studies.
2.2. Inclusion criteria
(i) had to be between the ages of 18 and 70 (inclusive) and in
general good health,
(ii) required to possess a minimum of two hypersensitive
teeth which were anterior to the molars and demonstrat-
ed cervical erosion/abrasion or gingival recession; and for
which a tactile sensitivity stimuli score of 10–50 g of force
(Yeaple Probe) and an air blast stimuli score of 2 or 3 (Schiff
Cold Air Sensitivity Scale) were presented at the baseline
examination,
(iii) required to be available for the eight week duration of the
study and to sign an informed consent form.
Subjects were excluded from the study if they:
(i) had gross oral pathology, chronic disease, advanced
periodontal disease, had undergone treatment for peri-
odontal disease (within the last 12 months), or if they had
hypersensitive teeth with a mobility greater than one,
(ii) had teeth with extensive/defective restorations (including
prosthetic crowns), suspected pulpitis, caries, cracked
enamel or that were used as abutments for removable
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tamines, antidepressants, sedatives, tranquilizers, anti-
inflammatory drugs or daily analgesics within one month
prior to the start of the study or if they started taking them
during the course of the study,
(iii) were pregnant or lactating women, individuals who were
participating in any other clinical study or who had
participated in a desensitizing dentifrice study or who
used a desensitizing dentifrice within the last three
months,
(iv) had a history of allergy to the test products, or allergies to
oral care/personal care consumer products or their
ingredients, or had existing medical conditions, which
precluded them from eating and drinking for periods up
to 4 h.
Prospective study subjects reported to the clinical facility
having refrained from all oral hygiene procedures, from
chewing gum for 8 h, and from eating and drinking for 4 h
prior to their examination. All prospective subjects who met
the inclusion/exclusion criteria and signed an informed
consent form received a baseline tactile hypersensitivity
and an air blast hypersensitivity evaluation, along with an
oral soft and hard tissue assessment. Qualifying subjects were
sequentially randomized using a list of random numbers
provided by study sponsors.
For each subject who qualified for participation in the
study, two hypersensitive teeth that satisfied the tactile and
air blast hypersensitivity enrollment criteria were identified
for evaluation throughout the study. Qualifying subjects were
stratified based on mean tactile and air blast hypersensitivity
baseline scores and randomly assigned within strata to one of
two study treatments: (1) a test mouthwash containing 0.8%
arginine, polyvinylmethyl ether/maleic acid (PVM/MA) copol-
ymer, pyrophosphates, and 0.05% sodium fluoride in an
alcohol-free base (‘‘Arginine Mouthwash’’) (Colgate-Palmolive
Company, New York, NY), or (2) a mouthwash (‘‘Negative
Control’’) in an alcohol-free base without any active ingre-
dients (Colgate-Palmolive Company, New York, NY).
Mouthwashes were over-wrapped to maintain the blinding
of the study participants, examiners and all study personnel.
Site personnel not involved in the clinical evaluations
distributed all test products in sealed opaque bags in an area
separate from the examination room. The three products were
letter coded.
Following treatment assignment, subjects were provided
with toothpaste (Colgate1 Cavity Protection containing
1450 ppm fluoride) and a soft toothbrush (Colgate1 Adult
Extra Clean) for home use. All mouthwashes were over-
wrapped in their original package to maintain the double-
blind study design. Subjects were instructed to brush their
teeth and then to immediately rinse their mouth with 20 mL of
their assigned mouthwash for 30 s twice daily (morning and
evening) and to use only the toothpaste, toothbrush and
mouthwash provided. Subjects were not allowed to floss or
use inter-dental stimulators or to eat or drink for 30 min after
rinsing. There were no restrictions regarding diet or smoking
habits during the course of the study.
Oral soft and hard tissue assessments, as well as tactile
and air blast hypersensitivity follow-up evaluations ofbaseline-designated study teeth, were conducted after
two, four and eight weeks of product use. Subjects were
requested to return to the clinical facility having refrained
from all oral hygiene procedures and from chewing gum for
8 h, and from eating and drinking for 4 h prior to their
scheduled visit. All examinations were performed by the
same dental examiner, using the same procedures as
employed at baseline. Subjects were also interviewed with
respect to the presence of adverse events and the use of
concomitant medications.
3. Clinical scoring procedures
3.1. Tactile dentin hypersensitivity assessment
Tactile dentin hypersensitivity was assessed by use of the
Model 200A Electronic Force Sensing Probe developed by
Yeaple Research of Pittsford, NY. The application of this probe
for dental hypersensitivity testing utilizing a #19 explorer tip at
a pre-set force measured in grams was employed.
Teeth were evaluated for tactile hypersensitivity48,49 in the
following manner:
(1) The subject was instructed to respond at the point where
he/she first experienced discomfort.
(2) The explorer tip of the probe was applied to the buccal
surface of each hypersensitive tooth at the CEJ.
(3) The explorer tip was stroked perpendicular to the tooth
beginning at a pre-set force of 10 g (0.01 kg) and increased
by 10 g (0.05 kg) increments until the subject experienced
discomfort, or until 50 g (0.05 kg) of force was applied.
Subjectwise scores were calculated by averaging the values
measured on the two baseline-designated study teeth.
3.2. Air blast dentin hypersensitivity assessment
Teeth were evaluated for air blast dentin hypersensitivity in
the following manner:
(1) The sensitive tooth was isolated from the adjacent teeth
(mesial and distal) by placement of the examiner’s fingers
over the adjacent teeth.
(2) Air was delivered from a standard dental unit air syringe at
60 psi (4.22 kgf/cm2)  5 psi (0.35 kgf/cm2) and 70 8F
(21)  3 8F (16). The air was directed at the exposed
buccal surface of the hypersensitive tooth for 1 s from a
distance of approximately 1 cm.
(3) The Schiff Cold Air Sensitivity Scale50 was used to assess
subject response to this stimulus. This scale was scored as
follows:
0 – Subject did not respond to air stimulus.
1 – Subject responded to air stimulus but did not request
discontinuation of stimulus.
2 – Subject responded to air stimulus and requested
discontinuation or moved from stimulus.
3 – Subject responded to air stimulus, considered stimulus
to be painful and requested discontinuation of the
stimulus
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The dental examiner visually examined the oral cavity and
peri-oral area using a dental light and dental mirror at all
hypersensitivity evaluations. This examination included an
evaluation of the soft and hard palate, gingival mucosa,
buccal, mucosa, mucogingival fold areas, tongue, sublingual
and submandibular areas, salivary glands, and the tonsilar
and pharyngeal areas.
3.4. Adverse events
Adverse events were obtained from an interview with the
subjects and from a dental examination by the investigator.
4. Statistical methods
Statistical analyses were performed separately for the tactile
hypersensitivity assessments and air blast hypersensitivity
assessments. Comparisons of the treatment groups with
respect to gender were performed using a chi-square analysis
and for age an analysis of variance (ANOVA). Comparisons of
the treatment groups with respect to baseline-adjusted
tactile hypersensitivity and air blast hypersensitivity scores
at the follow-up examinations were performed using an
analysis of covariance (ANCOVA). All statistical tests ofhypotheses were two sided, and employed a level of
significance of a = 0.05.
5. Results
Ninety (90) subjects entered the study, from December 29, 2010
to February 28, 2011 complied with the protocol, and
completed the eight week clinical study (Fig. 1). A summary
of the gender and age of the study population is presented in
Table 1. The treatment groups did not differ significantly with
respect to either of these characteristics. Throughout the
study, there were no adverse events on the oral soft or hard
tissues of the oral cavity observed by the examiner or reported
by the subjects when questioned.
Table 2 presents a summary of the mean tactile hypersen-
sitivity scores for each of the treatment groups at each of the
measurement time points. Table 3 presents a summary of the
mean air blast scores for each of the treatment groups at each
of the measurement time points. Tables 2 and 3 also contain a
comparison of the percent difference in the two treatments at
each of the time points. At baseline there was not a
statistically significant difference between the two treatment
groups with respect to either mean tactile or mean air blast
hypersensitivity scores.
After two weeks of product use, the Arginine Mouthwash
group exhibited a statistically significant improvement in
Table 1 – Summary of age & gender for subjects in the
eight week clinical study.
Treatment Number of subjects Age
Male Female Total Mean Range
Arginine Mouthwash 20 25 45 46.2 21–63
Negative Control 20 25 45 46.6 25–67
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to the Negative Control group by 22.1%. With respect to air
blast scores, the Arginine group exhibited a statistically
significant reduction in baseline-adjusted mean hypersensi-
tivity score relative to the Negative Control group by 14.2%.
After four weeks of product use, the Arginine Mouthwash
group exhibited a statistically significant improvement in
baseline-adjusted mean tactile hypersensitivity score relative
to the Negative Control group by 37.1%. With respect to air
blast scores, the Arginine group exhibited a statistically
significant reduction in baseline-adjusted mean hypersensi-
tivity score relative to the Negative Control group by 24.1%.
After eight weeks of product use, the Arginine Mouthwash
group exhibited a statistically significant improvement in
baseline-adjusted mean tactile hypersensitivity score relative
to the Negative Control group by 44.6%. With respect to air
blast scores, the Arginine group exhibited a statistically
significant reduction in baseline-adjusted mean hypersensi-
tivity score relative to the Negative Control group by 24.0%.
6. Discussion
Dentin is structurally composed of hydroxyapatite mineral
and organic components and is formed by the odontoblasts
during tooth development. It contains thousands of tubules
which run perpendicular to the pulp chamber and which are
formed as the odontoblasts migrate away from the dentin-
enamel junction during dentin formation.51,52 Dentin is
normally covered by enamel or cementum. When teeth
erupt, the gingival margin seals the teeth leaving the coronal
portion exposed in the oral cavity and the root portion of the
tooth protected from the external environment. Exposed
dentin and open tubules patent to the pulp cause hypersen-
sitive teeth.10
The mechanism by which dentin hypersensitivity occurs is
that external stimulus triggers a pressure change in the dentin
fluid, the fluid movement transmits a signal to the odontoblast
process, and the process carries the stimulus from the tooth
surface toward the nerve ending in the dentin tubule, resultingTable 2 – Summary of the tactile hypersensitivity scores for s
Treatment No. Baselinea
(mean  SD)
2-Week
(mean  SD)
% Differen
2-weekb
Arginine Mouthwash 45 17.22  4.20 26.33  11.79 22.1% 
Negative Control 45 17.00  5.78 21.56  8.84 
a Treatments are not statistically significantly different from each other
b At each time point, statistically significantly percentage differences ( p
are shown.in pain. Once the stimulus is removed, the pressure within the
tubule returns to normal and the pain is alleviated.
There are two scientifically accepted approaches to treat
dentin hypersensitivity. One is to occlude exposed tubules and
the other is to suppress nerve activity. With tubular occlusion,
the tooth is treated with a physical or chemical agent that
forms a layer that mechanically occludes the dentin tubules
and prevents pulpal fluid flow, thereby, decreasing dentin
hypersensitivity.53,54 In suppressing nerve activity, the tooth is
treated with an agent that increases the nerve depolarization
threshold, and thus modulates or suppresses the sensation of
pain.55,56
Research has indicated that the ideal dentin hypersensi-
tivity treatment should mimic natural desensitizing processes
leading to spontaneous occlusion of open dentin tubules.9
Kleinberg and coworkers developed a dentin hypersensitivity
treatment consisting of 8% arginine (an amino acid found in
saliva), and calcium carbonate. This technology mimics
saliva’s natural process of plugging and sealing open dentin
tubules.57 When applied to exposed dentin, open dentin
tubules are sealed with a plug that reduces dentin hypersen-
sitivity.1 This technology was first introduced as a desensitiz-
ing prophylaxis paste with 8% arginine and calcium carbonate
for professional use.
Research continued with the arginine/calcium carbonate
combination and led to the development of a dentifrice
containing 8.0% arginine, calcium carbonate, and sodium
monofluorophosphate. The dentifrice physically seals den-
tin tubules with a plug that contains arginine, calcium
carbonate and phosphate. The plug is resistant to normal
pulpal pressures and to acid challenge and thereby reduces
dentin fluid flow and reduces dentin hypersensitivity.Clini-
cal studies have shown that this dentifrice containing 8%
arginine, calcium carbonate and 1450 ppm sodium mono-
fluorophosphate provides superior efficacy in reducing
dentin hypersensitivity as compared to a leading desensitiz-
ing dentifrice containing 2% potassium ion.40–42 In addition,
direct topical self-application of the product to the sensitive
site has been shown to provide instant relief of dentin
sensitivity.43–45
As an alternative or a complement to using a desensitizing
dentifrice, a new mouthwash formulation has been developed
which contains 0.8% arginine, in combination with pyropho-
sphates and a PVM/MA copolymer to trigger tubule occlusion,
and 0.05% sodium fluoride. This new mouthwash was
compared to a Negative Control mouthwash containing
0.05% sodium fluoride to determine its relative effects in
relieving dentin hypersensitivity over an eight week period.ubjects who completed the eight-week study.
ce 4-Week
(mean  SD)
% Difference
4-weekb
8-Week
(mean  SD)
% Difference
8-weekb
32.44  12.41 37.1% 38.22  10.23 44.6%
23.67  12.13 26.44  12.60
 at baseline.
 < 0.05) as per the ANCOVA comparison of baseline-adjusted means
Table 3 – Summary of the air blast hypersensitivity scores for subjects who completed the eight-week study.
Treatment No. Baselinea
(mean  SD)
2-Week
(mean  SD)
% Difference
2-weekb
4-Week
(mean  SD)
% Difference
4-weekb
8-Week
(mean  SD)
% Difference
8-weekb
Arginine
Mouthwash
45 2.33  0.39 1.81  0.67 14.2% 1.42  0.46 24.1% 1.30  0.57 24.0%
Negative
Control
45 2.33  0.40 2.11  0.57 1.87  0.60 1.71  0.54
a Treatments are not statistically significantly different from each other at baseline.
b At each time point, statistically significantly percentage differences ( p < 0.05) as per the ANCOVA comparison of baseline-adjusted means
are shown.
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 after two weeks, four weeks and eight weeks of product use,
the Arginine Mouthwash group exhibited statistically
significant ( p < 0.05) improvements (22.1%, 37.1% and
44.6% respectively) in tactile hypersensitivity scores as
compared to the Negative Control mouthwash group.
 after two weeks, four weeks and eight weeks of product use,
the Arginine Mouthwash group exhibited statistically
significant ( p < 0.05) reductions (14.2%, 24.1% and 24.0%
respectively) in air blast hypersensitivity scores as com-
pared to the Negative Control Mouthwash group.
7. Conclusion
The results of this double-blind clinical study support the
conclusion that the Arginine Mouthwash using the Pro-
ArginTM Mouthwash Technology and containing 0.8% argi-
nine, PVM/MA copolymer, pyrophosphates, and 0.05% sodium
fluoride in an alcohol-free base provides a significant reduc-
tion in dentin hypersensitivity after eight weeks of product use
as compared to a Negative Control mouthwash in an alcohol-
free base.
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